Brief Title: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Follicular Lymphoma;   Marginal Zone Lymphoma;   Mantle Cell Lymphoma;   Diffuse Large B Cell Lymphoma;   Advanced Solid Tumor;   Non-small Cell Lung Cancer;   Metastatic Melanoma Interventions:   Drug: BGB-10188;   Drug: Zanubrutinib;   Drug: Tislelizumab Sponsor:   BeiGene Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials